



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GRANETO et al.

GROUP ART UNIT: 1614

SERIAL NO.: 10/667,622

EXAMINER: Laura Stockton

FILED: September 22, 2003

DATE: May 18, 2004

TITLE:

CELECOXIB PRODRUG

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97-1.98

Commissioner of Patents Box 1450 Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement previously filed. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Patricia K. Fitzsimmons Attorney for Applicants Registration No. 52,894

(314) 274-1490

Pharmacia Corporation of Pfizer Inc. Global Patent Department Post Office Box 1027 St. Louis, MO 63006

.9			Sneet 1 of 1
FORM PTO-1449 U.S. COMMERCE, PATENT AND TRAI	DEPARTMENT OF	ATTY. DOCKET	APPLICATION NO.:
COMMERCE, PATENT AND TRAI	DEMARK OFFICE	NO.: 01084/2/US	10/667,622
SUPPLEMENTAL INFORMATIO STATEMENT BY APPL		INVENTOR: Graneto e	al.
(Use several sheets if nec	essarv)	Filed: 09/22/2003	Group: 1614

U.S. PATENT DOCUMENTS

Examiner										Filing Date If
Initial	Document Number			Date	Name	Class	Subclass	Appropriate		

FOREIGN PATENT DOCUMENTS

Examiner												Transla	tion
Initial	Document Number						Date	Country	Class	Subclass	Yes	No	
		_						· -					
											· -		
									_				
										Ĭ			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
	Mamidi, Rao N.V.S. et al.: "Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats" BIOPHARMACEUTICS & DRUG DISPOSITION (2002), 23(7), 273-282.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whethe Draw line through citation if not in conformance a next communication to applicant.	r or not citation is in conformance with MPEP 609. nd not considered. Include copy of this form with

(Form PTO-1449)